AAPL349.18+5.35 (+1.56%) ▲|ABBV288.90+2.91 (+1.02%) ▲|ABT104.40+1.76 (+1.71%) ▲|ACN242.99-0.41 (-0.17%) ▼|ADBE246.45-3.31 (-1.33%) ▼|AMAT424.03+8.03 (+1.93%) ▲|AMD569.90-8.54 (-1.48%) ▼|AMGN458.24+6.41 (+1.42%) ▲|AMT184.31+0.56 (+0.30%) ▲|AMZN246.11-8.50 (-3.34%) ▼|AVGO344.50-7.31 (-2.08%) ▼|AXP324.21+6.27 (+1.97%) ▲|BA173.94+6.80 (+4.07%) ▲|BAC51.73+0.88 (+1.73%) ▲|BKNG150.18+2.24 (+1.51%) ▲|BLK1,171.22+13.34 (+1.15%) ▲|BMY60.68+0.11 (+0.17%) ▲|BNY149.96+1.37 (+0.92%) ▲|BRK-B543.61+3.27 (+0.61%) ▲|C126.42+2.31 (+1.86%) ▲|CAT656.78-56.60 (-7.93%) ▼|CL92.35+0.66 (+0.72%) ▲|CMCSA21.98+0.41 (+1.90%) ▲|COF208.78+3.90 (+1.90%) ▲|COP149.24+0.18 (+0.12%) ▲|COST989.27+6.54 (+0.67%) ▲|CRM231.59-10.52 (-4.35%) ▼|CSCO109.12-1.17 (-1.06%) ▼|CVS90.59+0.64 (+0.71%) ▲|CVX230.10+0.90 (+0.39%) ▲|DE659.11+18.44 (+2.88%) ▲|DHR236.92+2.85 (+1.22%) ▲|DIS110.76+1.72 (+1.57%) ▲|DUK125.60+2.03 (+1.64%) ▲|EMR170.71+3.00 (+1.79%) ▲|FDX308.94+4.36 (+1.43%) ▲|GD369.13+14.78 (+4.17%) ▲|GE312.18+11.05 (+3.67%) ▲|GEV904.82+26.79 (+3.05%) ▲|GILD161.15+1.95 (+1.22%) ▲|GM85.76+3.28 (+3.98%) ▲|GOOG283.17-38.72 (-12.03%) ▼|GOOGL285.10-39.80 (-12.25%) ▼|GS934.68+9.51 (+1.03%) ▲|HD325.65+8.09 (+2.55%) ▲|HON221.15+1.89 (+0.86%) ▲|IBM254.77+1.55 (+0.61%) ▲|INTC92.46-3.07 (-3.21%) ▼|INTU330.00+1.81 (+0.55%) ▲|ISRG447.80+3.62 (+0.82%) ▲|JNJ274.90+3.86 (+1.42%) ▲|JPM344.08+4.78 (+1.41%) ▲|KO92.30+0.57 (+0.62%) ▲|LIN499.84-8.32 (-1.64%) ▼|LLY1,371.02+82.72 (+6.42%) ▲|LMT646.44+16.69 (+2.65%) ▲|LOW204.43+6.03 (+3.04%) ▲|LRCX257.50+3.68 (+1.45%) ▲|MA635.83+25.52 (+4.18%) ▲|MCD255.36+4.86 (+1.94%) ▲|MDLZ62.09+0.22 (+0.36%) ▲|MDT96.78+2.00 (+2.11%) ▲|META629.89+17.40 (+2.84%) ▲|MMM176.37+3.57 (+2.07%) ▲|MO75.57+2.58 (+3.53%) ▲|MRK147.55+6.62 (+4.70%) ▲|MS192.58+2.45 (+1.29%) ▲|MSFT524.03-6.99 (-1.32%) ▼|MU945.99-37.24 (-3.79%) ▼|NEE82.20+1.18 (+1.46%) ▲|NFLX62.09+0.10 (+0.15%) ▲|NKE38.39+1.24 (+3.32%) ▲|NOW112.01-38.12 (-25.39%) ▼|NVDA213.52-1.87 (-0.87%) ▼|ORCL139.64-4.91 (-3.39%) ▼|PEP132.93+0.30 (+0.23%) ▲|PFE29.73+0.28 (+0.94%) ▲|PG159.01+0.75 (+0.47%) ▲|PLTR194.55-2.27 (-1.15%) ▼|PM205.74+3.10 (+1.53%) ▲|QCOM183.24+0.27 (+0.15%) ▲|RTX200.65+4.81 (+2.45%) ▲|SBUX104.56+1.36 (+1.32%) ▲|SCHW89.72+0.96 (+1.08%) ▲|SO93.07+1.55 (+1.69%) ▲|SPG214.71+3.47 (+1.64%) ▲|T21.03+0.33 (+1.59%) ▲|TMO709.33+5.18 (+0.74%) ▲|TMUS148.77+0.69 (+0.47%) ▲|TSLA405.89+1.67 (+0.41%) ▲|TXN309.48-0.35 (-0.11%) ▼|UBER65.29+0.02 (+0.02%) ▲|UNH405.79-1.31 (-0.32%) ▼|UNP299.08+1.28 (+0.43%) ▲|UPS106.50+0.88 (+0.83%) ▲|USB60.65+1.05 (+1.76%) ▲|V409.94+9.34 (+2.33%) ▲|VZ43.70+0.52 (+1.19%) ▲|WFC85.09+1.42 (+1.69%) ▲|WMT121.05+2.28 (+1.92%) ▲|XOM182.01-0.01 (-0.01%) ▼|AAPL349.18+5.35 (+1.56%) ▲|ABBV288.90+2.91 (+1.02%) ▲|ABT104.40+1.76 (+1.71%) ▲|ACN242.99-0.41 (-0.17%) ▼|ADBE246.45-3.31 (-1.33%) ▼|AMAT424.03+8.03 (+1.93%) ▲|AMD569.90-8.54 (-1.48%) ▼|AMGN458.24+6.41 (+1.42%) ▲|AMT184.31+0.56 (+0.30%) ▲|AMZN246.11-8.50 (-3.34%) ▼|AVGO344.50-7.31 (-2.08%) ▼|AXP324.21+6.27 (+1.97%) ▲|BA173.94+6.80 (+4.07%) ▲|BAC51.73+0.88 (+1.73%) ▲|BKNG150.18+2.24 (+1.51%) ▲|BLK1,171.22+13.34 (+1.15%) ▲|BMY60.68+0.11 (+0.17%) ▲|BNY149.96+1.37 (+0.92%) ▲|BRK-B543.61+3.27 (+0.61%) ▲|C126.42+2.31 (+1.86%) ▲|CAT656.78-56.60 (-7.93%) ▼|CL92.35+0.66 (+0.72%) ▲|CMCSA21.98+0.41 (+1.90%) ▲|COF208.78+3.90 (+1.90%) ▲|COP149.24+0.18 (+0.12%) ▲|COST989.27+6.54 (+0.67%) ▲|CRM231.59-10.52 (-4.35%) ▼|CSCO109.12-1.17 (-1.06%) ▼|CVS90.59+0.64 (+0.71%) ▲|CVX230.10+0.90 (+0.39%) ▲|DE659.11+18.44 (+2.88%) ▲|DHR236.92+2.85 (+1.22%) ▲|DIS110.76+1.72 (+1.57%) ▲|DUK125.60+2.03 (+1.64%) ▲|EMR170.71+3.00 (+1.79%) ▲|FDX308.94+4.36 (+1.43%) ▲|GD369.13+14.78 (+4.17%) ▲|GE312.18+11.05 (+3.67%) ▲|GEV904.82+26.79 (+3.05%) ▲|GILD161.15+1.95 (+1.22%) ▲|GM85.76+3.28 (+3.98%) ▲|GOOG283.17-38.72 (-12.03%) ▼|GOOGL285.10-39.80 (-12.25%) ▼|GS934.68+9.51 (+1.03%) ▲|HD325.65+8.09 (+2.55%) ▲|HON221.15+1.89 (+0.86%) ▲|IBM254.77+1.55 (+0.61%) ▲|INTC92.46-3.07 (-3.21%) ▼|INTU330.00+1.81 (+0.55%) ▲|ISRG447.80+3.62 (+0.82%) ▲|JNJ274.90+3.86 (+1.42%) ▲|JPM344.08+4.78 (+1.41%) ▲|KO92.30+0.57 (+0.62%) ▲|LIN499.84-8.32 (-1.64%) ▼|LLY1,371.02+82.72 (+6.42%) ▲|LMT646.44+16.69 (+2.65%) ▲|LOW204.43+6.03 (+3.04%) ▲|LRCX257.50+3.68 (+1.45%) ▲|MA635.83+25.52 (+4.18%) ▲|MCD255.36+4.86 (+1.94%) ▲|MDLZ62.09+0.22 (+0.36%) ▲|MDT96.78+2.00 (+2.11%) ▲|META629.89+17.40 (+2.84%) ▲|MMM176.37+3.57 (+2.07%) ▲|MO75.57+2.58 (+3.53%) ▲|MRK147.55+6.62 (+4.70%) ▲|MS192.58+2.45 (+1.29%) ▲|MSFT524.03-6.99 (-1.32%) ▼|MU945.99-37.24 (-3.79%) ▼|NEE82.20+1.18 (+1.46%) ▲|NFLX62.09+0.10 (+0.15%) ▲|NKE38.39+1.24 (+3.32%) ▲|NOW112.01-38.12 (-25.39%) ▼|NVDA213.52-1.87 (-0.87%) ▼|ORCL139.64-4.91 (-3.39%) ▼|PEP132.93+0.30 (+0.23%) ▲|PFE29.73+0.28 (+0.94%) ▲|PG159.01+0.75 (+0.47%) ▲|PLTR194.55-2.27 (-1.15%) ▼|PM205.74+3.10 (+1.53%) ▲|QCOM183.24+0.27 (+0.15%) ▲|RTX200.65+4.81 (+2.45%) ▲|SBUX104.56+1.36 (+1.32%) ▲|SCHW89.72+0.96 (+1.08%) ▲|SO93.07+1.55 (+1.69%) ▲|SPG214.71+3.47 (+1.64%) ▲|T21.03+0.33 (+1.59%) ▲|TMO709.33+5.18 (+0.74%) ▲|TMUS148.77+0.69 (+0.47%) ▲|TSLA405.89+1.67 (+0.41%) ▲|TXN309.48-0.35 (-0.11%) ▼|UBER65.29+0.02 (+0.02%) ▲|UNH405.79-1.31 (-0.32%) ▼|UNP299.08+1.28 (+0.43%) ▲|UPS106.50+0.88 (+0.83%) ▲|USB60.65+1.05 (+1.76%) ▲|V409.94+9.34 (+2.33%) ▲|VZ43.70+0.52 (+1.19%) ▲|WFC85.09+1.42 (+1.69%) ▲|WMT121.05+2.28 (+1.92%) ▲|XOM182.01-0.01 (-0.01%) ▼|
17.5 C
New York
Thursday, October 29, 2026

Tag: period

newsFORsourcecompanycontentinformationreleases1market

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA’s 85th Scientific Session

CAMBRIDGE, Mass., June 21, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the presentation of...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

ROSEN, LEADING INVESTOR COUNSEL, Encourages Reddit, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RDDT

NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Reddit, Inc. (NYSE: RDDT) between October 29, 2024 and May 20, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 18, 2025.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Red Cat Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCAT

NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) --

WHY: New York, N.Y., June 21, 2025. Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline.

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

William Stern’s Cardiff Redefines Working Capital for Small Businesses

Cardiff CEO William Stern is modernizing the merchant cash advances (MCA) concept, also known as Revenue Based Financing. SAN DIEGO, June 21, 2025 /PRNewswire/ -- Traditional...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions

In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly...

Analyzing Annuities’ Reputation: Evaluating Their Role in Strategic Financial Planning

Running out of money in retirement is a significant concern among investors, often surpassing even the fear of death. While maximizing contributions to an...

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and...

New Research on Abbott’s Healthy Food Rx Program Shows ‘Food is Medicine’ Approach Helps People Living With Diabetes Eat Better and Feel Healthier

Randomized, controlled clinical trial presented as a late-breaking poster at ADA's Scientific Sessions shows people participating in Abbott's Healthy Food Rx ate more vegetables and...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPeriod

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers